Skip to main content
Lydia Visser
PhD

My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.

ADAM17 up-regulation in renal transplant dysfunction and non-transplant-related renal fibrosis
Published in: Nephrology Dialysis Transplantation
Background. Interstitial fibrosis and tubular atrophy (IF/TA) is an important cause of renal function loss and ischaemia-reperfusion (I/R) injury is considered to play an important role in its pathophysiology. The aim of the present study was to investigate the role of a disintegrin and metalloproteinase 17 (ADAM17) in human renal allograft disease and in experimental I/R injury of the kidney. Methods. We studied the expression of ADAM17 messenger RNA (mRNA) in IF/TA and control kidneys by reverse transcription-polymerase chain reaction and in situ hybridization. Moreover, we assessed ADAM17-mediated...
Gemma M. Mulder, Wynand B. W. H. Melenhorst, Johanna W. A. M. Celie, Niels J. Kloosterhuis, Jan-Luuk Hillebrands, Rutger J. Ploeg, Marc A. Seelen, Lydia Visser, Marcory C. R. F. van Dijk, Harry van Goor
Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups (Retraction of vol 118, pg 5211, 2011)
Published in: Blood
X. Huang, K. Kushekhar, Roeland J. M. Nolte, W. Kooistra, Lydia Visser, Ilby Bouwman, N. Kouprie, R. Veenstra, G. van Imhoff, G. Imhoff, B. Olver, R. S. Houlston, S. Poppema, A. Diepstra, B. Hepkema, A. van den Berg
Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin’s lymphoma
Published in: Haematologica
BACKGROUND: The c-Met signaling pathway regulates a variety of biological processes, including proliferation, survival and migration. Deregulated c-Met activation has been implicated in the pathogenesis and prognosis of many human malignancies. We studied the function and prognostic significance of c-Met and hepatocyte growth factor protein expression in patients with classical Hodgkin’s lymphoma. DESIGN AND METHODS: Expression of c-Met and its ligand, hepatocyte growth factor, were determined by immunohistochemistry. Prognostic values were defined in cohorts of German and Dutch patients with classical Hodgkin’s lymphoma. Functional studies were performed on...
Chuanhui Xu, Wouter Plattel, Anke van den Berg, Nele Ruether, Xin Huang, Miao Wang, Debora de Jong, Hans Vos, Gustaaf van Imhoff, Andreas Viardot, Peter Moeller, Sibrand Poppema, Arjan Diepstra, Lydia Visser
Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin’s lymphoma
Published in: Haematologica
BACKGROUND: Plasma thymus and activation-regulated chemokine is a potential biomarker for classical Hodgkin’s lymphoma. To define its value as a marker to monitor treatment response, we correlated serial plasma thymus and activation-regulated chemokine levels with clinical response in newly diagnosed and relapsed classical Hodgkin’s lymphoma patients. DESIGN AND METHODS: Plasma was collected from 60 (39 early stage and 21 advanced stage) newly diagnosed classical Hodgkin’s lymphoma patients before, during, and after treatment, and from 12 relapsed patients before and after treatment. Plasma thymus and activation-regulated chemokine levels were...
HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
Published in: PLoS ONE
HLA-A2 protects from EBV+ classical Hodgkin lymphoma (cHL) in Western Europe, but it is unknown whether this protective effect also exists in the Chinese population. We investigated the association of HLA-A2 and specific common and well documented HLA-A2 subtypes with EBV stratified cHL patients (n = 161) from the northern part of China. Quantitative-PCR and sequence-based subtyping was performed to identify HLA-A2 positive samples and their subtypes. 67 (42%) of the cHL patients were EBV+. There were no significant differences in percentages of HLA-A2 positivity between cHL and...
Xin Huang, Bouke Hepkema, Ilja Nolte, Kushi Kushekhar, Theo Jongsma, Rianne Veenstra, Sibrand Poppema, Zifen Gao, Lydia Visser, Arjan Diepstra, Anke van den Berg